Clinuvel Pharmaceuticals Future Growth
Future criteria checks 2/6
Clinuvel Pharmaceuticals is forecast to grow earnings and revenue by 12.9% and 10.9% per annum respectively. EPS is expected to grow by 12.6% per annum. Return on equity is forecast to be 17.6% in 3 years.
Key information
12.9%
Earnings growth rate
12.6%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 10.9% |
Future return on equity | 17.6% |
Analyst coverage | Low |
Last updated | 23 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 113 | 43 | 49 | 46 | 5 |
6/30/2025 | 99 | 37 | 41 | 42 | 5 |
6/30/2024 | 89 | 35 | 36 | 42 | 5 |
12/31/2023 | 82 | 30 | 36 | 42 | N/A |
9/30/2023 | 80 | 30 | 36 | 40 | N/A |
6/30/2023 | 78 | 31 | 36 | 37 | N/A |
3/31/2023 | 74 | 29 | 39 | 40 | N/A |
12/31/2022 | 70 | 26 | 43 | 44 | N/A |
9/30/2022 | 68 | 24 | 41 | 42 | N/A |
6/30/2022 | 66 | 21 | 39 | 40 | N/A |
3/31/2022 | 62 | 22 | 33 | 34 | N/A |
12/31/2021 | 57 | 24 | 27 | 27 | N/A |
9/30/2021 | 53 | 24 | 23 | 23 | N/A |
6/30/2021 | 48 | 25 | 18 | 19 | N/A |
3/31/2021 | 43 | 23 | N/A | N/A | N/A |
12/31/2020 | 38 | 21 | 17 | 19 | N/A |
9/30/2020 | 35 | 18 | 15 | 16 | N/A |
6/30/2020 | 33 | 15 | 13 | 14 | N/A |
3/31/2020 | 32 | 15 | N/A | N/A | N/A |
12/31/2019 | 32 | 15 | 16 | 16 | N/A |
9/30/2019 | 32 | 16 | 17 | 17 | N/A |
6/30/2019 | 31 | 18 | 18 | 18 | N/A |
3/31/2019 | 29 | 17 | 16 | 17 | N/A |
12/31/2018 | 27 | 16 | 15 | 15 | N/A |
9/30/2018 | 26 | 15 | 13 | 13 | N/A |
6/30/2018 | 25 | 13 | 12 | 12 | N/A |
3/31/2018 | 21 | 10 | 10 | 10 | N/A |
12/31/2017 | 17 | 6 | 8 | 8 | N/A |
9/30/2017 | 17 | 7 | N/A | 9 | N/A |
6/30/2017 | 17 | 7 | N/A | 10 | N/A |
3/31/2017 | 14 | 5 | N/A | 7 | N/A |
12/31/2016 | 12 | 3 | N/A | 4 | N/A |
9/30/2016 | 9 | 0 | N/A | -1 | N/A |
6/30/2016 | 7 | -3 | N/A | -5 | N/A |
3/31/2016 | 5 | -5 | N/A | -5 | N/A |
12/31/2015 | 4 | -6 | N/A | -5 | N/A |
9/30/2015 | 4 | -8 | N/A | -5 | N/A |
6/30/2015 | 3 | -10 | N/A | -5 | N/A |
3/31/2015 | 3 | -10 | N/A | -5 | N/A |
12/31/2014 | 3 | -10 | N/A | -5 | N/A |
9/30/2014 | 3 | -8 | N/A | -5 | N/A |
6/30/2014 | 3 | -6 | N/A | -5 | N/A |
3/31/2014 | 3 | -6 | N/A | -6 | N/A |
12/31/2013 | 2 | -6 | N/A | -7 | N/A |
9/30/2013 | 2 | -6 | N/A | -7 | N/A |
6/30/2013 | 2 | -7 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLVL.Y's forecast earnings growth (12.9% per year) is above the savings rate (2.4%).
Earnings vs Market: CLVL.Y's earnings (12.9% per year) are forecast to grow slower than the US market (14.1% per year).
High Growth Earnings: CLVL.Y's earnings are forecast to grow, but not significantly.
Revenue vs Market: CLVL.Y's revenue (10.9% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: CLVL.Y's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLVL.Y's Return on Equity is forecast to be low in 3 years time (17.6%).